Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies by Lecumberri, R. (Ramón) et al.
| 1258 | haematologica/the hematology journal | 2005; 90(9)
Ramón Lecumberri
José A. Páramo
Eduardo Rocha
Anticoagulant treatment and survival in cancer
patients. The evidence from clinical studies
The association between cancer andthrombosis was described for thefirst time in the nineteenth century.1
Since then, great advances have been
achieved in the field, leading to a better
understanding of the pathophysiological
mechanisms involved in the pathogenesis
of this bi-directional association. On the
one hand, cancer development induces a
chronic hypercoagulable state that, added
to other predisposing conditions in cancer
patients (e.g. immobility, surgery, central
venous catheters, antineoplastic treat-
ments), leads to an increased risk of
venous thromboembolism (VTE).2 But on
the other hand, the hemostatic system also
plays a key role in the progression of malig-
nant disease. In fact, cancer patients who
develop VTE have a poorer prognosis over
time in comparison with patients without
thrombosis.3 Furthermore, it has been
reported that a persistent activation of the
hemostatic pathway, with increased
thrombin generation, is associated with an
increased incidence of clinical malignan-
cies, especially of the digestive tract.4 In
addition, plasma levels of coagulation acti-
vation markers are strong predictors of
cancer survival.5 During the last few
decades there has been growing evidence
pointing to possible benefits of anticoagu-
lant treatment in cancer patients, in terms
of cancer progression and survival, that
would surpass the benefit achieved by the
anti-thrombotic effect.6 The hypothesis
that anticoagulants influence cancer pro-
gression has been investigated in numer-
ous experimental in vitro and in vivo stud-
ies, showing that these drugs (especially
heparins) can interfere with cancer cell
proliferation, tumor growth, angiogenesis,
development of hematogenous metasta-
sis, immune system reactions or drug
resistance.7-9 Experimental observations
were supported by results obtained after
post-hoc analysis of data obtained in some
old studies on VTE treatment in cancer
patients, and led to the design of new
studies specifically aimed to evaluate the
effect of anticoagulant drugs on cancer
progression and survival in cancer
patients. In particular, four new clinical
studies with low molecular weight
heparins (LMWH) have been published in
the last year, renewing the interest in this
field. This review will focus on the role of
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The association between cancer and an increased incidence of venous thromboem-
bolism (Trousseau syndrome) is well characterized and recent studies have shown that
the hemostatic system plays a key role at different stages in the process of tumorige-
nesis. Anticoagulant drugs therefore appear to be an attractive strategy in cancer ther-
apy, with an effect that would surpass the benefit of preventing thrombosis. This
hypothesis was initially supported by the post-hoc analysis of clinical trials not prima-
rily designed to evaluate the effect of anticoagulants, mainly low molecular weight
heparins (LMWH), on cancer survival. Other studies regarding the addition of unfrac-
tionated heparin or oral anticoagulants to standard cancer treatment offered controver-
sial results. However, recent investigations among cancer patients without deep
venous thrombosis, with cancer-related mortality as the primary end point, suggest
that at least in some patients LMWH may exert an antineoplastic effect in vivo and
alter the natural history of malignant disease by increasing the response rates and,
therefore, improving survival. Additional research on this field is needed to clarify the
biological mechanisms involved and to answer yet unsolved questions such as the
types of tumor and stages of disease most suitable for this treatment as well as how
to optimize treatment regimens.
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anticoagulant treatment and survival in cancer
patients in the light of recent clinical trials. The liter-
ature contains studies providing both indirect and
direct evidence about a potential effect of anticoagu-
lants in cancer treatment (Table 1). Emphasis is
placed on low molecular weight heparins.
Pathogenetic mechanisms in cancer and thrombosis
Cancer patients often show activation of blood
coagulation and impairment of fibrinolysis that may
result in the development of a thrombotic diathe-
sis.10,11 The pathogenesis of cancer-related thrombosis
is complex and multifactorial. The mechanisms
involved include the capacity of tumor cells to direct-
ly produce and release molecules with procoagulant
or fibrinolytic activity: tissue factor, cancer procoag-
ulant, urokinase-type plasminogen activator, tissue-
type plasminogen activator, plasminogen activator
inhibitor-1, among others.12 Also, tumor cells interact
with host cells (mainly endothelial cells, platelets and
monocytes) inducing activation and release of differ-
ent pro-coagulant mediators.12 However, as men-
tioned above, the link between the hemostatic sys-
tem and cancer is bi-directional. Tumor growth is
dependent on angiogenesis, and it has been shown
that components of the coagulation cascade (tissue
factor, thrombin, fibrin) and platelets can influence
tumor vessel development by both clotting-depend-
ent and clotting-independent mechanisms, including
upregulation of pro-angiogenic proteins such as vas-
cular endothelial growth factor (VEGF) or cleaving
protease-activated receptors.13,14
In addition, tumor-cell induced thrombin genera-
tion and platelet activation are involved in the
process of metastasis. Cancer cells bind to activated
platelets and fibrin inside the circulating blood pre-
venting tumor cells from immune recognition and
destruction. The tumor cell-fibrin-platelet complex is
then able to bind to endothelial cells with subsequent
extravasation and secondary distant growth.8
Therefore, anticoagulants would appear an attrac-
tive treatment for patients with cancer, although
their effectiveness and mechanism of action are still
far from being completely clarified.
Biological antineoplastic effects of anticoagulants
The biological antitumor effects of anticoagulant
drugs have recently been reviewed7,15 and will, there-
fore, be described only briefly. While vitamin K
antagonists have been reported to exert an anticancer
effect, mainly through their anticoagulant action,
heparins also show coagulation-independent anti-
neoplastic properties (Figure 1).
Heparins can influence proliferation of cancer cells
through inhibition of proto-oncogene expression,
inhibition of kinase phosphorylation, or induction of
apoptosis. However, in several animal models of
spontaneous metastasis, heparin failed to affect local
growth of transplanted tumors.7
Angiogenesis is a complex multi-step process
involving endothelial cell proliferation, migration,
degradation of extracellular matrix and formation of
new capillary structures. Heparins, especially
LMWH, can interfere with binding of growth factors
to their receptors. Small heparin fragments reduce
vascular endothelial growth factor activity and com-
pete with heparan sulfates in the extracellular matrix
that store growth factors and prevent them from pro-
Table 1. Classification of studies supporting the existence of an
effect of anticoagulant drugs on cancer.
Studies providing indirect evidence
∑  Studies comparing LMWH vs UFH in the initial treatment of VTE
∑  Studies comparing LMWH vs OAT as secondary prophylaxis of VTE
∑  Studies comparing LMWH vs UFH as VTE prophylaxis after cancer surgery
Studies providing direct evidence
∑  Evaluation of survival in cancer patients treated with standard treatment + oral 
anticoagulants or standard treatment + placebo/no treatment.
∑  Evaluation of survival in cancer patients treated with standard treatment + UFH
or standard treatment + placebo/no treatment.
∑  Evaluation of survival in cancer patients treated with standard treatment + 
LMWH or standard treatment + placebo/no treatment.
Figure 1. Potential coagulation-independent anticancer properties
of heparins suggested by experimental studies. Ch:
Chemotherapy; P-Gp: P-glycoprotein.
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teolytic degradation. In addition, heparins can affect
angiogenesis by altering the structure of fibrin matri-
ces, and an inhibitory effect on proliferation and
migration of endothelial cells has also been
described. Moreover, heparins decrease tissue factor
expression (tissue factor enhances angiogenesis by
upregulating vascular endothelial growth factor
expression). A recent report has shown that the
inhibitory effect of a LMWH (tinzaparin) on
endothelial tube formation is associated with the
release of tissue factor pathway inhibitor.16
On the other hand, heparins can modulate activa-
tion of leukocytes, inhibit adhesion of leukocytes to
endothelium and increase natural killer cell activity.17
The biological importance of these effects of
heparins on the immune system in cancer needs to
be clarified.
The development of metastasis is also affected by
heparins, through inhibition of adhesion of cancer
cells to extracellular matrix proteins, such as
fibronectin or laminin, or to endothelial cells (as a
result of interfering with selectins) and cancer cell
migration (inhibition of heparanases is probably
involved).7 Experimental animal models of metastasis
have shown that shortly after intravenous injection
of cancer cells there is a transient decrease in the cir-
culating platelet count as a consequence of formation
of tumor cell-platelet aggregates.18 These aggregates
allow tumor cells to survive (escaping the immune
response) and facilitate their arrest in narrow capillar-
ies within different organs developing distant metas-
tasis. Animals pre-treated with LMWH showed less
thrombocytopenia after tumor cell inoculation and
developed fewer distant metastases than controls.19
Finally, a recent in vitro study reported an inhibito-
ry effect of heparin on P-glycoprotein-mediated mul-
tidrug resistance, and so heparin would appear to be
a potential chemosensitizer that may increase the
efficacy of antineoplastic therapies.20
In conclusion, although there are some conflicting
results, basic research provides strong data support-
ing an effect of anticoagulants (especially heparins)
on tumor biology.
Anticoagulants in cancer patients: indirect evidence
Three different types of studies, not primarily
designed to evaluate the effect on cancer mortality,
suggest a possible effect of LMWH on cancer sur-
vival: a) LMWH versus unfractionated heparin (UFH)
as initial treatment of VTE in cancer patients; b)
LMWH versus oral anticoagulants as secondary pro-
phylaxis of VTE in cancer patients; c) LMWH as VTE
prophylaxis in cancer surgery.
LMWH vs UFH in the initial treatment of VTE
In 1992 Green et al. reported a significant difference
in cancer-related mortality after analyzing the data
from two randomized studies comparing LMWH
and UFH in the treatment of proximal deep vein
thrombosis.21-23 Combining both studies, patients
with cancer receiving LMWH had a survival advan-
tage over those treated with UFH. After a follow-up
of 3-6 months, there had been 21/67 (31%) cancer
deaths in the standard heparin group and 7/62 (11%)
in the LMWH group (p=0.005). That difference could
not be attributed to fatal thrombotic or hemorrhagic
events.
Similar data were obtained from two meta-analy-
ses of all available randomized clinical trials in which
LMWH was compared with UFH in the treatment of
VTE24,25 (Table 2). The most recent one included nine
studies and over 3500 patients with VTE, 629 with
cancer.25 Patients were randomized to receive either
subcutaneous LMWH or intravenous UFH for 5 to 10
days, followed by oral anticoagulants for at least 3
months. In patients without cancer, there were no
differences in 3-month mortality between patients
treated with LMWH (39/1481) or UFH (41/1471).
However, 117 out of 629 cancer patients died within
the first 3 months of follow-up (46/306 in the LMWH
group and 71/323 in the UFH group). The pooled
odds ratio for the 3-month mortality in cancer
patients was 0.61 (95%CI 0.40 – 0.93) in favor of
LMWH. Differences in 3-month mortality between
the two groups remained after adjusting for some
prognostic factors (age, gender, tumor characteris-
tics), supporting the conclusion that the treatment
had a real effect. Again, the differences observed
could not be attributed to a higher incidence of fatal
bleeding or thrombotic complications in the UFH
group, which were equally infrequent in the overall
population (1.1% versus 1.3%). Although no data
regarding incidence of these fatal events in the cancer
group were available, this low incidence makes a sig-
nificant difference between cancer patients receiving
LMWH or UFH unlikely. Of course, these results
must be interpreted with caution. None of these
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Table 2. Mortality during follow-up (3-6 months) in cancer patients
with VTE after initial treatment with UFH or LMWH.
Meta-analysis Mortality Odds Ratio 
UFH LMWH (95% CI)
Green et al. 21/67 7/62 0.28 
199221 (31%) (11%) (0.1 – 0.7)
Siragusa et al. 23/81 10/74 0.33 
199624 (28%) (14%) (0.1 – 0.8)
Hettiarachchi et al. 71/323 46/306 0.61
199925 (22%) (15%) (0.4 – 0.9)
studies was designed to evaluate the effect of the
anticoagulant drug on cancer mortality; in fact, can-
cer patients were only a small percentage of the
whole population included in the different studies, so
the possibility of bias due to uncontrolled distribu-
tion of confounding factors related to malignancy
cannot be ruled out. Moreover, it is difficult to estab-
lish how short-term LMWH treatment can reduce
cancer mortality. As a consequence, clear conclusions
about the benefits of LMWH on long-term survival
could not be drawn. Interestingly, however, recent in
vitro studies have shown that the heparin chain
length is responsible for the variable effects of
heparins on the hemostatic properties of endotheli-
um and angiogenesis.26,27 LMWH showed a stronger
inhibition of endothelial cell proliferation and forma-
tion of tubular-like structures than did UFH or a pen-
tasaccharide.
LMWH vs oral anticoagulants in the secondary
prophylaxis of VTE
In order to investigate whether LMWH was more
effective and safer than oral anticoagulant therapy in
preventing recurrent thromboembolism in patients
with cancer who had suffered a first episode of VTE,
676 patients were randomized to receive either dal-
teparin or a coumarin derivative for 6 months, in the
setting of a multicenter trial, the CLOT study.28
Dalteparin was more effective than oral anticoagu-
lants in reducing the risk of VTE recurrence (27/336
patients in the LMWH group and 53/336 patients in
the oral anticoagulant group; p=0.002) without
increasing the risk of bleeding (14% and 19%,
respectively). Mortality rates at 6 months were 39%
in the LMWH group and 41% in the oral anticoagu-
lant group (p=0.53), most of them related with cancer
progression. A further post-hoc analysis, performed
to determine any treatment-related difference in
mortality at 12 months in patients with solid tumors,
showed mortality rates during the 12-month follow-
up period of 59% in both the dalteparin group
(174/296 patients) and warfarin group (182/306
patients). However, there were differences if patients
with or without known metastasis were analyzed
separately.29 The probability of mortality at 12
months in patients with known metastasis was sim-
ilar in the dalteparin and warfarin groups (72% and
69%, respectively). In contrast, in the subgroup of
patients with non-metastatic solid tumor at random-
ization (n=150 patients) the cumulative mortality at
12 months was 20% (15/75) for those treated with
LMWH and 35% (26/75) for those treated with oral
anticoagulants (hazard ratio, 0.50 [95% CI
0.27–0.95], p=0.03). This difference in mortality
could not be attributed to treatment group differ-
ences in fatal pulmonary embolism, and did not
change after adjustment for other possible confound-
ing variables such as age, tumor type, cancer treat-
ment, ECOG status or type of thrombotic episode.
Once again, caution is required since results were
observed after a post-hoc analysis of a population not
defined a priori and the number of patients without
known metastasis included was relatively small (75
in each treatment group). In addition, the population
recruited was heterogeneous and some potential
confounding factors such as time from diagnosis of
the malignancy or previous antineoplastic therapies
were not considered. Furthermore, patients in the
CLOT trial were cancer patients with an objectively
diagnosed VTE, thus conclusions could only be
applied to that population. However, the results are
in line with those of recent trials designed to investi-
gate the influence of LMWH on cancer survival
(FAMOUS and MALT trials, see later).
In a previous study with a similar aim, 146 patients
with cancer and an objective diagnosis of VTE were
randomized to receive anticoagulant treatment with
a fixed dose of LMWH (enoxaparin 1.5 mg/Kg/day)
or oral warfarin (adjusted to achieve an international
normalized ratio –INR- between 2.0 and 3.0), for 3
months.30 During the study treatment period,
patients assigned to receive warfarin experienced a
higher incidence of recurrent VTE and major hemor-
rhages (composite end-point) than those treated with
LMWH (21.1% vs 10.5%; relative risk: 2.02, 95%CI,
0.88–4.65) (p=0.09). Mortality during the 3-month
study period was also higher in the warfarin group
(22.7%) than among patients receiving LMWH
(11.3%). However, this difference in mortality rate
was mainly due to fatal bleeds, cancer-related death
and cancer progression being similar in both groups.
After a 6-month follow-up period, cancer progression
was observed in 36.0% of patients randomized to
warfarin and in 33.8% of patients initially treated
with enoxaparin. No difference was observed regard-
ing overall mortality at 6 months either (38.7% in the
warfarin group and 31.0% in the LMWH-treated
patients) (p=0.25).
These results do not really argue against those
observed in the CLOT trial. In fact, the study lacked
enough power to address an effect of treatment on
cancer spread or mortality. Patients were followed
for 6 months and differences in mortality may
become evident after longer follow-up. Besides,
more than 50% of patients had metastatic disease, in
which the effect of LMWH on survival seems to be
lower according to the CLOT trial.
LMWH for VTE prophylaxis after cancer surgery
In a prospective, randomized, double-blind clinical
trial, 324 patients undergoing breast or pelvic cancer
surgery received antithrombotic prophylaxis with
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either a LMWH, certoparin (n=160), or UFH (n=164)
until day 7 post-operatively.31 Mortality after 650
days was lower in the certoparin group (5.7%) than
in the UFH-treated patients (15.6%) (p=0.006).
However, after a longer follow-up, 1050 days, mor-
tality in the LMWH and the UFH group was no
longer significantly different between groups (11.4%
and 18.4%, respectively; p=0.136). In the subgroup
analysis, among patients with breast cancer, there
was no treatment-related difference in mortality
either after 650 days or at day 1050 (p=0.367 and
p=0.812), whereas mortality at day 650 in patients
with pelvic cancer was reduced by almost 70% by
LMWH prophylaxis: 8.7% vs 28.6%; RR 0.30
(95%CI 0.11 – 0.85) (p=0.013). Mortality at day 1050
in patients with pelvic cancer treated with LMWH
group was still half of that in those receiving UFH
(15.2% vs 28.6%), although this difference was not
statistically significant (p=0.10). Again, these findings
were independent of whether the patient did or did
not develop VTE. Although this study included quite
a homogeneous group of cancer patients, the results
observed differed according to the type of tumor,
suggesting that stratification by tumor cell type and
stage is crucial.
On the other hand, in the Enoxacan II study, 332
patients undergoing planned curative surgery for
abdominal or pelvic cancer were randomly assigned,
after 6 to 10 days of anti-thrombotic prophylaxis
with enoxaparin 40 mg daily, to receive either enoxa-
parin or placebo for an additional 21 days.32 Extended
treatment with LMWH was associated with a signif-
icant reduction in the rates of VTE, both at the end of
the double blind phase and at 3 months, without
increasing the rates of bleeding or other complica-
tions. Mortality during the 3-month follow-up was
3.6% in the placebo group and 1.8% in the enoxa-
parin group, although the study lacked enough statis-
tical power to evaluate differences in mortality
between the groups. After a 1-year follow-up no dif-
ference in mortality was observed (7.7% and 9.5%,
respectively).33
Anticoagulants in cancer patients: direct evidence
Direct evidence comes from studies specifically
aimed to investigate the effect of anticoagulants on
cancer mortality. According to the type of anticoagu-
lant, these studies can be divided into three groups: a)
trials evaluating survival in cancer patients undergo-
ing oral anticoagulant therapy; b) trials evaluating the
effect of UFH on cancer survival; c) trials investigat-
ing the role of LMWH on cancer survival.
Oral anticoagulant therapy and survival in cancer
Although there were previous reports concerning a
beneficial effect of vitamin K antagonists on mortali-
ty in patients with cancer, the first randomized clini-
cal trial evaluating the role of warfarin on cancer sur-
vival in patients with different types of cancer, was
published by Zacharski et al., in the early eighties
(Veterans Administration Cooperative Study Nº 75).34
No differences in survival were observed between
warfarin-treated and control groups for non-small
cell lung, colorectal, head and neck and prostate can-
cers. However, warfarin treatment was associated
with a significantly longer time to disease progres-
sion (p=0.016) and improvement in survival
(p=0.018) in patients with small cell lung cancer.
The Cancer and Leukemia Group B (CALGB) con-
ducted a prospective randomized trial in patients
with extensive small cell lung cancer comparing two
chemotherapy regimens.35 In one group of patients,
warfarin, aimed to maintain a prolongation of the
prothrombin time between 1.5 to 2 times the control
value, added to chemotherapy was associated with
significantly increased objective response rates
(p=0.012). Failure-free survival and overall survival
improved in the warfarin-treated group, although the
differences observed did not reach statistical signifi-
cance (p=0.054 and p=0.098, respectively). On the
other hand, an overall increased incidence of hemor-
rhage in the warfarin group was observed, although
the rate of life-threatening hemorrhages was low
(4%).
Another randomized study by the same group
evaluated the effect of warfarin (to keep the pro-
thrombin time between 1.4 and 1.6 times the control
values) together with chemotherapy and radiation
therapy in patients with limited stage small cell lung
cancer.36 No significant differences were noted in
either response rates (89% in warfarin-treated
patients and 88% in controls; p=0.86), or overall sur-
vival (median 21.4 months in warfarin-treated
patients and 18.6 months in controls, p=0.12). A
trend towards a higher disease-free survival in the
warfarin group was observed (median 24.9 months
versus 13.7 months, p=0.09) only in a subgroup of
patients who received more intensive chemotherapy
treatment.
Two other studies did not find any beneficial effect
of warfarin on survival in patients with breast cancer
or colorectal cancer.37,38 A recent meta-analysis
showed that one-year mortality rates of patients
with various types of cancer was not significantly
influenced by the addition of vitamin K-antagonists
to chemotherapy (odds ratio 0.89; 95% CI: 0.70 –
1.13).39 After stratification by cancer type, the odds
ratio for 1-year mortality was 0.75 (95% CI: 0.44 –
1.16) in favor of warfarin in the subgroup with small
cell lung cancer, and 1.40 (95% CI: 0.65 – 3.00) in
favor of no additive treatment in colorectal cancer.
Thus it is not possible to conclude that oral anticoag-
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ulants have a beneficial effect on cancer survival. In
addition, there is special concern about the use of
vitamin K antagonists in cancer patients because of
the higher risk of bleeding complications in this pop-
ulation, and the difficulty of maintaining adequate
INR levels,40 which has prompted an increased use of
LMWH instead of oral anticoagulants in cancer
patients with VTE.
Interestingly, an antineoplastic effect of warfarin
was suggested by Schulman et al. in a randomized
study analyzing the duration of oral anticoagulant
therapy after a first episode of VTE.41 A new cancer
was diagnosed during follow-up in 15.8% of patients
treated with oral anticoagulants for 6 weeks, com-
pared with 10.3% in patients treated for 6 months
(odds ratio 1.6; 95% CI: 1.1–2.4). This difference
became evident only after two years of follow-up,
suggesting that the effect may be limited to small
cancers. However, a more recent prospective study
that randomized patients with a first episode of idio-
pathic VTE to receive oral anticoagulants for 3
months or 1 year found no difference in the incidence
of newly diagnosed overt cancer (6.2% and 8.7%,
respectively).42
UFH and survival in cancer
In a French study, 277 patients with small cell lung
cancer were randomized either to receive UFH
(n=138) or not (n=139). Subcutaneous injections of
heparin calcium (500 IU/Kg/day) were administered
for a period of 5 weeks, in addition to chemotherapy
and delayed thoracic radiotherapy.43 There were no
differences between the groups in terms of overall
response rates, but a difference was obtained in com-
plete response rate in favor of the heparin group
(33% vs 21%; p=0.03). The median survival was 317
days in the heparin-treated patients and 261 days in
the control group (p=0.01). The calculated odds ratio
of total 3-year mortality was 0.64 (95% CI 0.25 –
1.62) in favor of heparin. However, after subgroup
stratification according to the stage of the disease
(limited or extensive), the difference observed was
statistically significant only in the former group
(p=0.03). Hemorrhagic adverse events were not
increased in the heparin group, although patients
with high bleeding risk were not included. Thus, in
this study, UFH seemed to improve survival in
patients with small cell lung cancer, although the
effect seems restricted to patients with limited forms
of disease.
Another two randomized trials investigated the
effect of adjuvant intraportal infusion with heparin
and 5-fluorouracil in resectable colon cancer.44,45
Overall, 632 patients were randomized to no adju-
vant treatment (n=224), or intraportal infusion of 5-
fluorouracil together with continuous prophylactic
UFH (5000–10000 UI/24 h) for seven days post-oper-
atively (n=214), or intraportal UFH alone (n=194).
Three-year mortality rates were 16% in the control
group, 24% in the UFH alone group and 13% in the
UFH/5-fluorouracil group. The calculated odds ratio
of UFH compared with no treatment after surgery for
colon cancer was 1.66 (95% CI 1.02-2.71). Therefore,
in these series UFH seemed to show a detrimental
effect on cancer survival.
A meta-analysis of the previous studies, which also
separately evaluated four studies that either were not
randomized or included post-hoc analysis for the
long term effects of UFH on cancer patients,46
showed that 3-year mortality rates of patients who
received UFH or no UFH perioperatively for
resectable gatrointestinal cancer were 24% (187/786)
in the heparin group and 30% (195/649) in the
untreated group. The calculated odds ratio was 0.65
(95% CI 0.51-0.84) in favor of UFH prophylaxis.
It is, therefore, difficult to address whether there is
either improved survival or worse prognosis in
patients with malignancy receiving UFH.
LMWH and survival in cancer
A summary of recent studies aimed to evaluate the
effect of LMWH on cancer survival is provided in
Table 3. In the FAMOUS trial (Fragmin Advanced
Malignancy Outcome Study), 385 patients with
advanced solid cancer were randomized to receive
either dalteparin (5000 U/day) or placebo for up to
one year.47 Survival estimates at 1, 2 and 3 years after
randomization were 46%, 27% and 21% for the dal-
teparin group and 41%, 18% and 12% for patients
receiving placebo (p=0.19). The incidence of sympto-
matic VTE or bleeding was low during the study
period (2.4% and 4.7%, respectively, in the LMWH
group and 3.3% and 2.7%, respectively, in the place-
bo group). However, analysis of a subgroup of
patients, not defined a priori, with a better prognosis
(survival beyond 17 months, 55 patients in the dal-
teparin group and 47 in the placebo group) revealed a
significant advantage for LMWH-treated patients,
with a median survival time of 43.5 and 24.3 months,
respectively (survival estimates at 2 and 3 years after
randomization were 78% and 60% for the dalteparin
group vs 55% and 36% for the placebo group;
p=0.03). Thus, a potential antitumor effect of LMWH
could not be excluded.
Another recent multicenter randomized study
compared LMWH versus placebo in patients with
non-curable solid malignant tumors (the MALT
trial).48 A total of 302 patients were randomized to
receive a therapeutic dose of a LMWH (nadroparin)
for 2 weeks followed by 4 weeks of half this dose, or
placebo for 6 weeks. Patients were followed for a
minimum period of 3 months, and cumulative mor-
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tality from all causes was the primary efficacy out-
come. The overall hazard ratio was 0.75 (95% CI
0.59 – 0.96) in favor of LMWH, with the median sur-
vival being 8.0 months in the LMWH group and 6.6
months in the placebo group. The difference
between these groups became more evident in an a
priori defined subgroup of patients with better prog-
nosis, who had a life expectancy of at least 6 months,
in whom the hazard ratio was 0.64 (95% CI 0.45 –
0.90) in favor of LMWH, while the difference
observed in those with a life expectancy of less than
6 months was less pronounced (hazard ratio, 0.88;
95% CI, 0.62 – 1.25). The incidence of major hemor-
rhage during study treatment was 3% among the
LMWH recipients and 1% in the placebo group
(p=0.12).
Altinbas et al. have recently reported the results of
a randomized clinical trial of combination
chemotherapy with and without LMWH in small cell
lung cancer, aimed to determine whether the addi-
tion of LMWH improved cancer outcome.49 Eighty-
four previously untreated patients were randomized,
42 to each treatment group: chemotherapy with
cyclophosphamide, epirubicin and vincristine alone
(3-weekly cycles for six cycles) or chemotherapy plus
dalteparin (5000 U daily) until disease progression or
until the end of the chemotherapy. An objective
response was observed in 69.2% of patients receiv-
ing LMWH and in 42.5% of those treated with
chemotherapy alone (p=0.07). This difference was
more evident for patients with limited disease (n=48)
(91.4% versus 60.0%, p=0.02) compared with
patients with extensive disease at diagnosis (n=36)
(37.4% versus 13.3%, p=0.59). Differences in the 1-
and 2-year progression-free survival rates were favor-
able to chemotherapy+LMWH, 30.4% and 3.4% ver-
sus 11.7% and 0% (p=0.01). The 1- and 2-year over-
all survival rates were 51.3% and 17.2% for patients
treated with chemotherapy+LMWH and 29.5% and
0% for patients receiving chemotherapy alone
(p=0.01). The median survival was 13.0 months
(95% CI 9.83-16.17) and 8.0 months (95% CI 6.14-
9.86), respectively (p=0.01). In this study, differences
in progression-free survival and overall survival were
observed in both subgroups of patients, either with
limited or extensive disease. The addition of LMWH
to antineoplastic treatments appeared to be safe,
since toxicity consisted of a single episode of mild
bleeding during the treatment period in one patient
treated with LMWH, but larger multicenter studies
are necessary to confirm these promising results.
Indeed, although the results from these studies
seem to support an antineoplastic effect of LMWH,
several points deserve discussion. First, the tremen-
dous heterogenity among all clinical studies. Both the
FAMOUS and the MALT trials included patients with
different kinds of tumors, different stages, time from
diagnosis or previous treatments, while the study
performed by Altinbas included only patients diag-
nosed with a single type of cancer, but at different
stages (which eventually were associated with differ-
ent responses after the addition of dalteparin). The
effect of LMWH may not be the same on different
cancers. LMWH could be associated with an
improved survival in limited and advanced stages of
some type of cancer, while exert no effect, or be lim-
ited only to early phases in other tumors. Secondly,
the treatment regimens administered were diverse.
While Altinbas et al. and the FAMOUS trial used pro-
phylactic doses of LMWH during the study period, in
the MALT trial patients initially received a higher
dose of LMWH. The duration of the treatment peri-
od was different in all the trials, ranging from 6
weeks in the MALT study to 1 year in the FAMOUS
trial. Lastly, it cannot be excluded that a different
effect is obtained depending on the molecule used.
Each LMWH has its own characteristics regarding
molecular weight and distribution of the length of
heparin chains, which could be responsible for differ-
ences in the in vivo effect of the different agents, as
suggested by in vitro studies.
Conclusions
The real effect of anticoagulant treatment on can-
cer survival still remains to be determined. Although
some individual studies found a beneficial effect in
Table 3. Clinical trials evaluating the role of LMWH in cancer treatment.
Study LMWH Dose Treatment Period n Type of Cancer Stage Effect
Kakkar et al., 200447 Dalteparin 5000 UI/day 1 year 385 Solid Advanced Survival not improved*
Klerk et al., 200448 Nadroparin Therapeutic 2 weeks 302 Solid Advanced Increased survival#
Half dose 4 weeks
Altinbas et al., 200449 Dalteparin 5000 UI/day 18 weeks 84 Lung Limited and Increased response¶
(small cell) advanced rate and survival
*Benefit in subgroup of patients with better prognosis (survival beyond 17 months); #in subgroup of patients with life expectancy > 6 months; ¶in patients with limited
disease.
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selected cases, overall it is not possible to conclude
that UFH or oral anticoagulant have a positive effect
on cancer survival. However, the evidence suggesting
that LMWH have an antineoplastic effect seems
more consistent. Results from individual studies and
some meta-analyses show that at least some patients
with VTE and cancer treated with LMWH have a
better survival than patients treated with UFH or
warfarin. A similar effect has been described in can-
cer patients without a history of VTE. The addition
of LMWH to standard treatment regimens is safe and
could improve survival in some types of cancers. 
However, we are only at the starting point of an
attractive field. Basic research aimed to clarify the
mechanisms involved in the antineoplastic effect of
LMWH is urgently needed, and appropriately
designed clinical trials to assess unsolved questions
regarding the tumor biology-modifying effect of
LMWH (type of tumor and stages likely to respond,
treatment regimen, potential differences between
molecules) are required. 
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